Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2605-2610

  Wu, Chiao En ^a   Lin, Yung Chang ^a   Hong, Ji Hong ^a   Chuang, Cheng Keng ^a   Pang, See Tong ^a   Liaw, Chuang Chi ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Bladder cancer; Complete response; Concurrent chemoradiotherapy; Hydronephrosis

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONCURRENT CHEMORADIOTHERAPY; CYSTECTOMY; CYSTOSCOPY; FEMALE; FOLLOW UP; HUMAN; HYDRONEPHROSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTICLE; BLADDER CANCER; BLADDER TUMOR; COMPLETE RESPONSE; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MUSCLE TUMOR; PATHOLOGY; REMISSION; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY;

BLADDER CANCER; COMPLETE RESPONSE; CONCURRENT CHEMORADIOTHERAPY; HYDRONEPHROSIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; HYDRONEPHROSIS; LEUCOVORIN; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

MLCS; MLOWN;

EID: 84881365228     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Rodel C, Weiss C and Sauer R: Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 24: 5536-5544, 2006.
2. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA and BC2001 Investigators: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366: 1477-1488, 2012.
3. Given RW, Parsons JT, McCarley D and Wajsman Z: Bladdersparing multimodality treatment of muscle-invasive bladder cancer: A five-year follow-up. Urology 46:499-504, discussion p. 505, 1995.
4. Cervek J, Cufer T, Zakotnik B, Kragelj B, Borstnar S, Matos T and Zumer-Pregelj M: Invasive bladder cancer: Our experience with bladder sparing approach. Int J Radiat Oncol Biol Phys 41: 273-278, 1998.
5. Zapatero A, Martin de Vidales C, Marin A, Cerezo L, Arellano R, Rabadan M and Perez-Torrubia A: Invasive bladder cancer: A single-institution experience with bladder-sparing approach. Int J Cancer 90: 287-294, 2000.
6. Arias F, Dominguez MA, Martinez E, Illarramendi JJ, Miquelez S, Pascual I and Marcos M: Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organsparing program. Int J Radiat Oncol Biol Phys 47: 373-378, 2000.
7. Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M and Schrott KM and Sauer R: Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20: 3061-3071, 2002.
8. Peyromaure M, Slama J, Beuzeboc P, Ponvert D, Debre B and Zerbib M: Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: Report of a single institution. Urology 63: 73-77, 2004.
9. Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B and Orefici F: Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: Long-term results. Cancer 101: 2540-2548, 2004.
10. Hussain SA, Stocken DD, Peake DR, Glaholm JG, Zarkar A, Wallace DMA and James ND: Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 90: 2106-2111, 2004.
11. Kragelj B, Zaletel-Kragelj L, Sedmak B, Cufer T and Cervek J: Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 75: 44-47, 2005.
12. Bladder cancer. In: AJCC Cancer Staging Manual, 7th Edition Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A (eds.). New York, Springer, pp. 497-505, 2010.
13. Chen WC, Liaw CC, Chuang CK, Chen MF, Chen CS, Lin PY, Chang PL, Chu SH, Wu CT and Hong JH: Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 56: 726-733, 2003.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
15. Haleblian GE, Skinner EC, Dickinson MG, Lieskovsky G, Boyd SD and Skinner DG: Hydronephrosis as a prognostic indicator in bladder cancer patients. J Urol 160: 2011-2014, 1998.
16. Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE and Volkmer BG: Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol 51: 690-697, discussion 697-698, 2007.
17. Lin HY, Wang SZ, Chen JX, Chen LW and Xiao J: The prognostic value of hydronephrosis in bladder cancer treated by radical cystectomy. Urologia 78: 17-21, 2011.
18. Chapman DM, Pohar KS, Gong MC and Bahnson RR: Preoperative hydronephrosis as an indicator of survival after radical cystectomy. Urol Oncol 27: 491-495, 2009.
19. Kawashima A, Nakayama M, Kakuta Y, Abe T, Hatano K, Mukai M, Nagahara A, Nakai Y, Oka D, Takayama H, Yoshioka T, Hoshida Y, Itatani H, Nishimura K and Nonomura N: Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res 17: 2561-2569, 2011.